Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025932) USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025932 International Application No.: PCT/IB2018/055665
Publication Date: 07.02.2019 International Filing Date: 30.07.2018
IPC:
A61K 31/404 (2006.01) ,A61K 45/06 (2006.01) ,A61P 25/32 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
30
for treating abuse or dependence
32
Alcohol-abuse
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH
Inventors:
DOLMETSCH, Ricardo; US
GASPARINI, Fabrizio; CH
JOHNS, Donald; US
GOMEZ-MANCILLA, Baltazar; CH
Priority Data:
62/539,00831.07.2017US
Title (EN) USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE
(FR) UTILISATION DE MAVOGLURANT DANS LA RÉDUCTION DE L'UTILISATION D'ALCOOL OU DANS LA PRÉVENTION DE RECHUTE DANS L'UTILISATION D'ALCOOL
Abstract:
(EN) The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.
(FR) L'invention concerne l'utilisation de mavoglurant, ou d'un sel pharmaceutiquement acceptable de celui-ci : dans la réduction de l'utilisation d'alcool par un patient souffrant d'un trouble d'utilisation de l'alcool; dans la prévention d'une rechute dans l'utilisation d'alcool par un patient souffrant d'un trouble d'utilisation de l'alcool; dans la promotion de l'abstinence d'alcool par un patient souffrant d'un trouble d'utilisation de l'alcool; dans le traitement des symptômes de la dépression ou de l'anxiété associée à un trouble d'utilisation de l'alcool.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)